- Home
- ILAG vs APRE Comparison
ILAG vs APRE Comparison
Compare ILAG & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- APRE
- Stock Information
- Founded
- ILAG 1981
- APRE 2006
- Country
- ILAG Hong Kong
- APRE United States
- Employees
- ILAG N/A
- APRE N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ILAG Consumer Discretionary
- APRE Health Care
- Exchange
- ILAG Nasdaq
- APRE Nasdaq
- Market Cap
- ILAG 11.1M
- APRE 9.4M
- IPO Year
- ILAG 2022
- APRE 2019
- Fundamental
- Price
- ILAG $0.65
- APRE $1.54
- Analyst Decision
- ILAG
- APRE Strong Buy
- Analyst Count
- ILAG 0
- APRE 1
- Target Price
- ILAG N/A
- APRE $20.00
- AVG Volume (30 Days)
- ILAG 716.4K
- APRE 32.9K
- Earning Date
- ILAG 04-28-2025
- APRE 11-06-2025
- Dividend Yield
- ILAG N/A
- APRE N/A
- EPS Growth
- ILAG N/A
- APRE N/A
- EPS
- ILAG N/A
- APRE N/A
- Revenue
- ILAG $7,506,551.00
- APRE $841,012.00
- Revenue This Year
- ILAG N/A
- APRE N/A
- Revenue Next Year
- ILAG N/A
- APRE N/A
- P/E Ratio
- ILAG N/A
- APRE N/A
- Revenue Growth
- ILAG 16.50
- APRE N/A
- 52 Week Low
- ILAG $0.34
- APRE $1.41
- 52 Week High
- ILAG $1.21
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- ILAG 56.76
- APRE 43.27
- Support Level
- ILAG $0.47
- APRE $1.49
- Resistance Level
- ILAG $0.96
- APRE $1.66
- Average True Range (ATR)
- ILAG 0.09
- APRE 0.08
- MACD
- ILAG 0.02
- APRE 0.00
- Stochastic Oscillator
- ILAG 37.16
- APRE 27.00
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.